Zenas BioPharma (NASDAQ:ZBIO) Shares Gap Up After Insider Buying Activity

Zenas BioPharma, Inc. (NASDAQ:ZBIO) shares gapped up before the market opened on Tuesday after an insider bought additional shares in the company. The stock had previously closed at $16.91, but opened at $17.92. Zenas BioPharma shares last traded at $17.1280, with a volume of 103,687 shares trading hands.

Specifically, CEO Leon O. Moulder, Jr. purchased 60,000 shares of the stock in a transaction that occurred on Monday, May 18th. The stock was acquired at an average cost of $16.88 per share, with a total value of $1,012,800.00. Following the transaction, the chief executive officer owned 96,928 shares of the company’s stock, valued at $1,636,144.64. This represents a 162.48% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and issued a $44.00 target price on shares of Zenas BioPharma in a research note on Friday. Citigroup restated a “buy” rating on shares of Zenas BioPharma in a research note on Thursday. Guggenheim upped their target price on Zenas BioPharma from $45.00 to $55.00 and gave the company a “buy” rating in a report on Monday, March 16th. Zacks Research raised Zenas BioPharma from a “strong sell” rating to a “hold” rating in a research report on Friday. Finally, Morgan Stanley upped their price objective on Zenas BioPharma from $21.00 to $22.00 and gave the company an “equal weight” rating in a research note on Thursday. Six research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Zenas BioPharma presently has a consensus rating of “Moderate Buy” and a consensus price target of $44.29.

Key Stories Impacting Zenas BioPharma

Here are the key news stories impacting Zenas BioPharma this week:

• Positive Sentiment: CEO Leon O. Moulder, Jr. bought 60,000 shares at $16.88 each, a purchase worth about $1.0 million, signaling insider confidence in Zenas BioPharma’s outlook. Article Title
• Positive Sentiment: Zenas BioPharma announced it will present Phase 3 INDIGO trial results for obexelimab in IgG4-related disease at the EULAR 2026 Congress, a near-term clinical catalyst that could draw investor attention. Article Title
• Neutral Sentiment: HC Wainwright maintained a Buy rating and $44 price target, but lowered earnings estimates across several periods, including Q2, Q3, Q4 2026 and FY2026-FY2030, reflecting a more cautious profit outlook.
• Negative Sentiment: The analyst’s lower EPS forecasts suggest Zenas BioPharma may face stronger-than-expected losses over the next several years, which likely pressured sentiment on the stock.

Zenas BioPharma Stock Up 2.5%

The stock’s 50-day moving average price is $21.04 and its two-hundred day moving average price is $26.62. The stock has a market capitalization of $1.09 billion, a P/E ratio of -2.04 and a beta of -0.61. The company has a current ratio of 11.94, a quick ratio of 11.94 and a debt-to-equity ratio of 1.04.

Zenas BioPharma (NASDAQ:ZBIO) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($1.46) earnings per share for the quarter, topping the consensus estimate of ($1.47) by $0.01. During the same period in the prior year, the company posted ($0.80) EPS. As a group, research analysts expect that Zenas BioPharma, Inc. will post -4.25 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Zenas BioPharma

A number of hedge funds and other institutional investors have recently bought and sold shares of ZBIO. Quarry LP grew its position in shares of Zenas BioPharma by 34.5% in the third quarter. Quarry LP now owns 1,134 shares of the company’s stock valued at $25,000 after purchasing an additional 291 shares in the last quarter. Russell Investments Group Ltd. purchased a new position in Zenas BioPharma during the 3rd quarter valued at about $30,000. GF Fund Management CO. LTD. purchased a new position in Zenas BioPharma during the 4th quarter valued at about $38,000. BNP Paribas Financial Markets increased its position in shares of Zenas BioPharma by 120.0% during the third quarter. BNP Paribas Financial Markets now owns 3,146 shares of the company’s stock valued at $70,000 after buying an additional 1,716 shares during the period. Finally, CWM LLC lifted its holdings in shares of Zenas BioPharma by 48.3% in the fourth quarter. CWM LLC now owns 2,178 shares of the company’s stock worth $79,000 after buying an additional 709 shares in the last quarter.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.